Status:
COMPLETED
Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan
Lead Sponsor:
UNICEF
Collaborating Sponsors:
Pak Emirates Military Hospital Rawalpindi
Conditions:
Covid19
Cytokine Release Syndrome
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Beyond supportive care, there are currently no proven treatment options for coronavirus disease (COVID-19) and related pneumonia, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)...
Detailed Description
Long title: Role of different investigational treatments alone or in combination to treat moderate, severe and critical COVID-19 in addition to standard treatment; An Open label, Phase 2 Study Clinica...
Eligibility Criteria
Inclusion
- PCR positive confirmed COVID-19
- Admitted in hospital
- willing patients to participate in trial
- Day of illness less than 14 days
- no contraindications to invasive procedure or novel therapies
Exclusion
- co morbidities with life expectancy less than 6 months
- Multi organ failure
- Septic shock before initiation of treatment
- Congestive cardiac failure (EF\<20%) (4)
- Those receiving immunotherapy, Anti-thymocyte globulin or hematopoietic stem cell transplant in recent past
- Patients of hematological or solid organ malignancies
Key Trial Info
Start Date :
April 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 20 2020
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT04492501
Start Date
April 1 2020
End Date
July 20 2020
Last Update
July 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pak Emirates Military Hospital
Rawalpindi, Punjab Province, Pakistan, 46000